Rockefeller Capital Management L.P. T Scan Therapeutics, Inc. Transaction History
Rockefeller Capital Management L.P.
- $47.9 Billion
- Q3 2025
A detailed history of Rockefeller Capital Management L.P. transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 200 shares of TCRX stock, worth $227. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200Holding current value
$227% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
76Shares Held
36.9MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$8.96 Million2.7% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$5.96 Million0.5% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$5.09 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$3.17 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$2.64 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $21.6M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...